Refocus Group

About Refocus Group

Refocus Group, Inc. is a medical device company specializing in the research and development of innovative treatments for human vision disorders, with a primary focus on presbyopia. Presbyopia is a condition that affects near vision, typically in individuals over the age of 40, making it difficult to see objects up close without reading glasses. The company's flagship product, the Micro Insert System, is an investigational medical device currently in clinical trials in the United States. This device aims to improve near vision in both eyes and reduce or eliminate the need for reading glasses among patients with presbyopia.

Refocus Group serves a niche market of patients suffering from presbyopia, offering a potential alternative to traditional reading glasses. The business model revolves around the development and eventual commercialization of the Micro Insert System, with revenue expected to be generated through the sale of this medical device upon regulatory approval.

The company operates within the medical device industry, focusing on ophthalmology and vision correction. By leveraging innovative technology and conducting rigorous clinical trials, Refocus Group aims to provide a safer and more effective solution for near vision correction.